Novo Nordisk Tests Oral Pill to Rival PCSK9 Injections for Cholesterol Control
A Phase 2 trial pits NNC0385-0434 tablets against evolocumab injections in high-risk cardiovascular patients — could a daily pill replace the shot?
Summary
Novo Nordisk is testing NNC0385-0434, an oral tablet designed to lower LDL cholesterol in people with established heart disease or high cardiovascular risk. This Phase 2 trial enrolled approximately 255 participants who received either the experimental pill at two doses (15 mg or 40 mg), a placebo, or evolocumab — an already-approved PCSK9 inhibitor given by injection every two weeks. The 22-week study aimed to determine how well the oral compound works compared to the injected gold standard. If effective, an oral PCSK9 inhibitor could dramatically improve patient adherence and accessibility, since many patients are reluctant to self-inject. The trial is now completed, and results are anticipated to inform whether this oral approach warrants larger Phase 3 development.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, and elevated LDL cholesterol is one of its most modifiable risk factors. While statins are first-line therapy, a significant portion of high-risk patients do not reach target LDL levels and require additional treatment. PCSK9 inhibitors like evolocumab have proven highly effective, reducing LDL by up to 60%, but their injectable format creates a real-world adherence barrier that limits their broader uptake.
This Phase 2 trial, sponsored by Novo Nordisk and registered on ClinicalTrials.gov (NCT04992065), investigated NNC0385-0434 — an experimental oral small-molecule compound — as a potential alternative to injectable PCSK9 inhibitors. Roughly 255 adults with atherosclerotic cardiovascular disease or high cardiovascular risk were randomized to receive NNC0385-0434 at 15 mg or 40 mg daily, a matching placebo, or evolocumab injections every two weeks. The study ran for approximately 22 weeks with nine clinic visits and two telephone follow-ups. A sub-study offered four additional visits for deeper pharmacokinetic and pharmacodynamic profiling.
Key outcomes likely measured LDL cholesterol reduction from baseline, safety, tolerability, and pharmacokinetics. The inclusion of evolocumab as an active comparator arm provides a meaningful clinical benchmark — allowing direct head-to-head comparison against an established standard of care.
If NNC0385-0434 demonstrates meaningful LDL lowering approaching that of evolocumab, the implications for cardiovascular prevention would be substantial. An oral PCSK9 inhibitor could simplify treatment regimens, improve patient acceptance, reduce healthcare administration costs, and potentially expand preventive treatment to broader populations including those averse to injections.
Important caveats apply. Full efficacy and safety results have not been published from this abstract alone. The trial was relatively small and short-term, and enrollment was restricted to women who could not become pregnant, which may limit generalizability. Phase 2 success does not guarantee Phase 3 effectiveness.
Key Findings
- NNC0385-0434 is a once-daily oral tablet targeting cholesterol reduction as an alternative to injectable PCSK9 inhibitors.
- Trial directly compared the oral compound against evolocumab, providing a head-to-head benchmark against approved therapy.
- Two doses (15 mg and 40 mg) were evaluated to establish dose-response and optimal therapeutic range.
- Phase 2 trial completed in ~255 high-cardiovascular-risk adults over 22 weeks with safety monitoring via ECG.
- An oral PCSK9 inhibitor, if effective, could address a major adherence gap in lipid-lowering therapy.
Methodology
Randomized, placebo-controlled, active-comparator Phase 2 trial enrolling approximately 255 adults with atherosclerotic cardiovascular disease or equivalent high risk. Participants were randomized to NNC0385-0434 15 mg, NNC0385-0434 40 mg, placebo, or evolocumab injection over a 22-week period with nine clinic visits and ECG monitoring. An optional pharmacokinetic sub-study included four additional visits.
Study Limitations
This summary is based on the clinical trial registration abstract only; full efficacy and safety data have not been reviewed. The trial is relatively small (n≈255) and short (22 weeks), limiting conclusions about long-term cardiovascular outcomes. Enrollment was restricted to women who could not become pregnant, which may reduce generalizability across the full patient population.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.